Find A Physician
More on "Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
Hospital News
More on "Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
- 9/11 Lifestyle Changes May Increase Cardiovascular Risk
- Americans Encouraged to Make Many Lifestyle Changes, Not Just One, to Reduce Cardiovascular Risk
- A NYC First: Patient Participates in Stem Cell Clinical Trial to Repair Heart Damaged by Severe Coronary Artery Disease
- Columbia Scientists Study Advantages of Using Web to Tailor Medical Information to Patients
- Columbia University Medical Center Study Shows Stress Test Saves Lives of Patients With Chest Pain
- Dean Antonio M. Gotto, Jr., Elected Fellow of American Academy of Arts and Sciences
- Dr. Antonio M. Gotto and Dr. Herbert Pardes Awarded Austrian Cross of Honor for Science and Art
- Genetic Medicine Program at Weill Cornell Receives Major Boost from The Starr Foundation
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Heart Health Inspiration & Strategies for the Whole Family
- Hot Flashes in Women Linked to High Blood Pressure, According to New Weill Cornell Study
- Is Garlic Good for Your Heart? A Review of the Evidence
- JAMA Article Looks at Data-Sharing in Clinical Trials for Heart Disease
- Larger Waistline Is Linked to Increased Risk for Heart Disease in Women
- Lovastatin Treatment Reduces Events in Patients at Varying Degrees of Coronary Risk and Reduces Need for Invasive Procedures
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- New Laser Technology Offers Promise for Heart Disease Patients
- New Methodology Gives Weill Cornell Team Insights into Psychological Value of Cardiac Stress Testing
- NewYork-Presbyterian/Columbia Announces State-of-the-Art, Vivian and Seymour Milstein Family Heart Center in Washington Heights
- NewYork-Presbyterian/Weill Cornell Physician-Scientists Present Findings at American Heart Association's Annual Conference
- NewYork-Presbyterian Hospital and Columbia University Medical Center Physician-Scientists Present Clinical Research at American Heart Association's Annual Conference
- Potential for Adult Stem Cells to Repair Hearts Damaged by Severe Coronary Artery Disease Investigated in Ongoing Study
- Researcher Predicts Paradigm Shift in Heart Disease Treatment
- Research Shows Cholesterol-Lowering Drug Lovastatin Reduces Risk of Heart Attack in Healthy Adults
- Weill Cornell Dean and Cardiovascular Expert Makes "Top Ten" Texas List
- Weill Cornell Receives $7.6 Million Federal Grant for Clinical Trials on New Ways To Change Behavior in Patients With Cardiopulmonary Disease
Research and Clinical Trials
More on "Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
Health Library
More on "Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
Clinical Services
More on "Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
- Advanced Diagnostics
- Alcohol Septal Ablation
- Angiograms
- Angioplasty and Stenting
- Artificial Heart Devices: LVAD
- Cardiac Electrophysiologic Studies and T-wave Alternans Testing
- Cardiac Magnetic Resonance Imaging (MRI)
- Cardiac Rehabilitation
- Cardiology
- Cardiothoracic Surgery
- Coronary Artery Bypass Surgery (Grafting)
- Echocardiograms
- Electrocardiograms (ECGs), Stress Tests, Holter Monitor and Event/Loop Recorders
- Heart Transplant Surgery
- Intravascular / Intracoronary and Intracardiac Ultrasound
- Nuclear Imaging For Heart Disease (PET scans, MUGA scans)
- Off-pump Surgery
- Pediatric Heart Surgery
- Preventive Cardiology
- Preventive Medicine and Nutrition
- Robotic Heart Surgery
- Surgery for Adult Congenital Heart Disease
- Tilt Testing
- Transmyocardial Revascularization
- Treatment of Peripheral Arterial Disease
"Bad" Cholesterol May Not Be the Best Predictor of Heart Disease Risk in Generally Healthy Individuals
New Insights from Landmark Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) of Lovastatin (Mevacor)
NEW YORK (Feb 7, 2000)
New information published this week in Circulation: Journal of the American Heart Association, from the landmark AFCAPS/TexCAPS study of lovastatin (Mevacor), suggests that low-density lipoprotein cholesterol (LDL-C, the "bad" cholesterol) is not the best predictor of risk for a major coronary event in generally healthy persons with average LDL-C and below average high-density lipoprotein cholesterol (HDL-C, the "good" cholesterol) levels.
Rather, as presented by Antonio M. Gotto, Jr., MD, DPhil, Dean of the Weill Medical College of Cornell University, and co-authors, concentrations of the proteins apolipoprotein (apo) B and apo AI were better predictors, especially when combined to form the apo B/AI ratio. These apolipoproteins are major components of LDL and HDL, respectively, and may be more sensitive measures of risk than LDL and HDL themselves.
In those without pre-existing heart disease who have average to mildly elevated total cholesterol and LDL-C, and below average HDL-C, LDL-C was not predictive of a major heart disease event unless it was considered in conjunction with HDL-C. Therefore, HDL-C measurement should be an essential component of risk assessment in men and women with average to mildly elevated LDL-C, in accord with previously reported epidemiological studies, such as the Framingham Heart Study.
Even in this cohort with a mean LDL-C at baseline of 150 mg/dL (lower than the initiation level recommended by current guidelines for drug treatment), there is no evidence to indicate a level of LDL-C below which lowering LDL-C and increasing HDL-C is not of coronary benefit.
After one year of treatment with lovastatin (Mevacor), on-treatment apo AI, apo B, and the ratio of apo B to apo AI were the best predictors of subsequent major coronary events. These findings suggest that further consideration should be given to measuring apos B and AI in risk assessment and treatment evaluation, and to incorporating them into future guidelines and goals in the United States.
Funding for this study was provided by Merck & Co Inc.
Disclaimer: The opinions expressed in this release are those of the authors and do not reflect those of the Department of Defense or the United States Air Force.
